SCHEMBL997361

SCHEMBL997361

COc1ccc(OBOc2ccc(OC)cc2[N+](=O)[O-])c([N+](=O)[O-])c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.55
MAPK1 P28482 2/20 0.55
RAB9A P51151 2/20 0.49
MAPT P10636 5/20 0.47
THRB P10828 1/20 0.47
HPGD P15428 2/20 0.47
AKR1C3 P42330 2/20 0.46
AKR1C2 P52895 2/20 0.46
KDM4E B2RXH2 2/20 0.45
NPC1 O15118 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HTT P42858 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
POLB P06746 1/20 0.44
MCOLN3 Q8TDD5 1/20 0.44
TLR9 Q9NR96 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28694866 0.87 ALDH1A1 (0.52) ALDH1A1MAPK1RAB9AMAPTTHRB
SCHEMBL4063903 0.86 ALDH1A1 (0.61) ALDH1A1MAPK1RAB9AMAPTTHRB
SCHEMBL29650091 0.86 ALDH1A1 (0.61) ALDH1A1MAPK1RAB9AMAPTTHRB
SCHEMBL28218587 0.84 ALDH1A1 (0.59) ALDH1A1MAPK1RAB9AMAPTTHRB
Cyanide SCHEMBL11163252 0.81 ALDH1A1 (0.56) ALDH1A1MAPK1RAB9AMAPTTHRB
SCHEMBL998108 0.79 TSHR (0.58) ALDH1A1MAPK1RAB9AMAPTHPGD
SCHEMBL11842385 0.79 RAB9A (0.57) ALDH1A1MAPK1RAB9AMAPTHPGD
SCHEMBL27560396 0.79 ALDH1A1 (0.54) ALDH1A1MAPK1RAB9AMAPTTHRB
SCHEMBL9035406 0.79 ALDH1A1 (0.54) ALDH1A1MAPK1RAB9AMAPTTHRB
SCHEMBL9035409 0.79 PDK1 (0.56) ALDH1A1MAPK1RAB9AMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919898-B1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS TIBOTEC PHARM LTD (IE) 2011-01-26 EP disclosed
US-7666834-B2 Macrocyclic inhibitors of hepatitis C virus TIBOTEC PHARMACEUTICALS LTD. (IE) 2010-02-23 US disclosed
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2009-04-23 US disclosed
EP-1919898-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS Tibotec Pharmaceuticals Ltd. (IE) 2008-05-14 EP disclosed
WO-2007014922-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus HCCS, CBR1, CYP2B6 ALDH1A1 2716/4885MAPK1 689/4885RAB9A 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.